Notes: January 8, 2021 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it intends to effect a reverse stock split of its common stock effective as of 4:30 pm EST on January 11, 2021 (the "Reverse Split"). The Reverse Split will be conducted on a 1-for-30 basis resulting in the Company's current issued share capital of 90,044,312 shares of common stock being consolidated into 3,001,377 shares of common stock, subject to adjustment for fractional shares which will be rounded to the nearest whole number. In addition, all of the Company's issued convertible securities will also be subject to the Reverse Split, with the exercise prices of the Company's outstanding convertible securities being adjusted accordingly.Following the Reverse Split, the Company's shares of common stock are intended but are not guaranteed to be listed on the NASDAQ Capital Market ("Nasdaq") on January 12, 2021 under the stock symbol LEXX and under the new CUSIP number 52886N406.